ArticleBMC infectious diseases2022
Epidemiology and genomic analysis of Klebsiella oxytoca from a single hospital network in Australia.
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 33 citations in OpenAlex.
- Global genomic landscape of theNew microbes and new infections · 2026Article
- Detection of opportunistic bacterial pathogens with intrinsic amoxicillin- and cephalosporin-resistance in wild koala faecal microbiomes.Microbiology (Reading, England) · 2026Article
- Decentralized nanopore genomics reveals diverseMicrobial genomics · 2026Article
- Epidemiology, Virulence Factors, and Antibacterial Resistance ofMedicina (Kaunas, Lithuania) · 2026Review
- A novel self-transmissible mega plasmid from extensively drug-resistantCurrent research in microbial sciences · 2026Article
- Genetic diversity, biochemical properties, epidemiology, and detection methods of IMP- and VIM-type carbapenemases.Clinical microbiology reviews · 2025Review
- The dark matter of bacterial genomic surveillance-antimicrobial resistance plasmid transmissions in the hospital setting.Journal of clinical microbiology · 2025Article
- Detection of ESBL-producingJournal of clinical microbiology · 2025Article
- Nodules-associated Klebsiella oxytoca complex: genomic insights into plant growth promotion and health risk assessment.BMC microbiology · 2025Article
- The First Report on the Structure of Polysaccharide Surface Antigens of the ClinicalInternational journal of molecular sciences · 2025Article
- Multiple regional outbreaks caused by global and local VIM-producing Klebsiella pneumoniae clones in Poland, 2006-2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- The results of polymerase chain reaction and MALDI-TOF mass spectrometry versus phenotypic distinction betweenFrontiers in microbiology · 2025Article
- Unraveling the genomic epidemiology and plasmid-mediated carbapenem resistance ofFrontiers in microbiology · 2025Article
- Genome assembly ofFrontiers in microbiology · 2025Article
- Article
- Evaluation of an expanded antibiotic resistance gene panel on prediction of antimicrobial susceptibility results for Gram-negative bacteria in blood cultures.Journal of clinical microbiology · 2024Article
- Comprehensive genomics reveals novel sequence types of multidrug resistant Klebsiella oxytoca with uncharacterized capsular polysaccharide K- and lipopolysaccharide O-antigen loci from the National Hospital of Uganda.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2024Article
- Epidemiology and antimicrobial resistance of toxin-producingHealth science reports · 2024Article
- Klebsiella oxytoca inhibits Salmonella infection through multiple microbiota-context-dependent mechanisms.Nature microbiology · 2024Article
- Core genome multilocus sequence typing (cgMLST) applicable to the monophyleticJournal of clinical microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundInfections caused by Klebsiella oxytoca are the second most common cause of Klebsiella infections in humans. Most studies have focused on K. oxytoca outbreaks and few have examined the broader clinical context of K. oxytoca.
methodsHere, we collected all clinical isolates identified as K. oxytoca in a hospital microbiological diagnostic lab across a 15-month period (n = 239). Whole genome sequencing was performed on a subset of 92 isolates (all invasive, third-generation cephalosporin resistant (3GCR) and non-urinary isolates collected > 48 h after admission), including long-read sequencing on a further six isolates with extended-spectrum beta-lactamase or carbapenemase genes.
resultsThe majority of isolates were sensitive to antimicrobials, however 22 isolates were 3GCR, of which five were also carbapenem resistant. Genomic analyses showed those identified as K. oxytoca by the clinical laboratory actually encompassed four distinct species (K. oxytoca, Klebsiella michiganensis, Klebsiella grimontii and Klebsiella pasteurii), referred to as the K. oxytoca species complex (KoSC). There was significant diversity within the population, with only 10/67 multi-locus sequence types (STs) represented by more than one isolate. Strain transmission was rare, with only one likely event identified. Six isolates had extended spectrum beta-lactamase (bla
conclusionWhilst antimicrobial resistance was rare, the resistance plasmids were similar to those found in other Enterobacterales, demonstrating that KoSC has access to the same plasmid reservoir and thus there is potential for multi-drug resistance. Further genomic studies are required to improve our understanding of the KoSC population and facilitate investigation into the attributes of successful nosocomial isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.